SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) VP Lan Xie sold 10,000 shares of SciClone Pharmaceuticals stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the completion of the sale, the vice president now owns 10,000 shares of the company’s stock, valued at $110,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) traded down 0.45% during mid-day trading on Wednesday, hitting $11.00. The company had a trading volume of 419,627 shares. SciClone Pharmaceuticals, Inc. has a 52-week low of $8.55 and a 52-week high of $11.43. The company has a market capitalization of $574.10 million, a P/E ratio of 13.56 and a beta of 1.71. The company has a 50-day moving average price of $10.98 and a 200 day moving average price of $10.16.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. SciClone Pharmaceuticals had a return on equity of 21.10% and a net margin of 25.18%. The company had revenue of $44.52 million during the quarter. On average, analysts forecast that SciClone Pharmaceuticals, Inc. will post $0.94 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/16/lan-xie-sells-10000-shares-of-sciclone-pharmaceuticals-inc-scln-stock.html.

A number of institutional investors have recently made changes to their positions in SCLN. LS Investment Advisors LLC boosted its position in shares of SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 8,355 shares during the period. BNP Paribas Arbitrage SA boosted its position in shares of SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,320 shares during the period. State of Alaska Department of Revenue boosted its position in shares of SciClone Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 10,213 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 4,503 shares during the period. Profund Advisors LLC purchased a new position in shares of SciClone Pharmaceuticals during the second quarter worth approximately $113,000. Finally, Municipal Employees Retirement System of Michigan boosted its position in shares of SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 310 shares during the period. Institutional investors own 73.26% of the company’s stock.

Separately, Maxim Group set a $14.00 price objective on SciClone Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 11th.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.